Answers are grounded in this paper and cite their sources.
Background: KN035 is a novel fusion protein of anti-PD-L1 single domain antibody and Fc, formulated for subcutaneous (SC) injection. A phase 1 dose escalation study was performed in the USA to evaluate and characterize the safety and tolerability, MTD, PK, PD and preliminary antitumor activity of single agent KN035 in patients (pts) with locally advanced or metastatic solid tumors.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: